It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target.
His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021.
Questions
- What are the challenges of drug development for non-alcoholic steatohepatitis (NASH)? (0:18)
- What is the rationale for targeting the farnesoid X receptor (FXR) in NASH? (1:07)
- What are the most promising FXR agonists in clinical development? (2:11)
- What other therapeutic targets and approaches are being investigated? (2:55)
Disclosures: Prof. Jean-François Dufour has been involved in advisory committees for Abbvie, Alientis, Allergan, Axcella, Bayer, Bristol-Myers Squibb, Eisai, Enyo Pharma, Falk, Genfit, Gilead Sciences, HepaRegeniX, Intercept, Ipsen, Inventiva, Madrigal, Merck, Novartis, Pfizer, Roche and Trilliome DTx; been involved with speaking and teaching for Bayer, Intercept and Genfit and declares royalties from BMJ Journals, Springer and UpToDate.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
